219 related articles for article (PubMed ID: 24610195)
1. Combined fenobam and amantadine treatment promotes robust antidyskinetic effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease.
Ko WK; Pioli E; Li Q; McGuire S; Dufour A; Sherer TB; Bezard E; Facheris MF
Mov Disord; 2014 May; 29(6):772-9. PubMed ID: 24610195
[TBL] [Abstract][Full Text] [Related]
2. Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease.
Kobylecki C; Hill MP; Crossman AR; Ravenscroft P
Mov Disord; 2011 Nov; 26(13):2354-63. PubMed ID: 21953539
[TBL] [Abstract][Full Text] [Related]
3. Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease.
Hill MP; Ravenscroft P; Bezard E; Crossman AR; Brotchie JM; Michel A; Grimée R; Klitgaard H
J Pharmacol Exp Ther; 2004 Jul; 310(1):386-94. PubMed ID: 15004218
[TBL] [Abstract][Full Text] [Related]
4. The mGluR5 negative allosteric modulator dipraglurant reduces dyskinesia in the MPTP macaque model.
Bezard E; Pioli EY; Li Q; Girard F; Mutel V; Keywood C; Tison F; Rascol O; Poli SM
Mov Disord; 2014 Jul; 29(8):1074-9. PubMed ID: 24865335
[TBL] [Abstract][Full Text] [Related]
5. TC-8831, a nicotinic acetylcholine receptor agonist, reduces L-DOPA-induced dyskinesia in the MPTP macaque.
Johnston TH; Huot P; Fox SH; Koprich JB; Szeliga KT; James JW; Graef JD; Letchworth SR; Jordan KG; Hill MP; Brotchie JM
Neuropharmacology; 2013 Oct; 73():337-47. PubMed ID: 23770260
[TBL] [Abstract][Full Text] [Related]
6. A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease.
Johnston TH; Lee J; Gomez-Ramirez J; Fox SH; Brotchie JM
Exp Neurol; 2005 Feb; 191(2):243-50. PubMed ID: 15649479
[TBL] [Abstract][Full Text] [Related]
7. Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys.
Blanchet PJ; Konitsiotis S; Whittemore ER; Zhou ZL; Woodward RM; Chase TN
J Pharmacol Exp Ther; 1999 Sep; 290(3):1034-40. PubMed ID: 10454475
[TBL] [Abstract][Full Text] [Related]
8. Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia.
Bezard E; Tronci E; Pioli EY; Li Q; Porras G; Björklund A; Carta M
Mov Disord; 2013 Jul; 28(8):1088-96. PubMed ID: 23389842
[TBL] [Abstract][Full Text] [Related]
9. A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys.
Rylander D; Iderberg H; Li Q; Dekundy A; Zhang J; Li H; Baishen R; Danysz W; Bezard E; Cenci MA
Neurobiol Dis; 2010 Sep; 39(3):352-61. PubMed ID: 20452425
[TBL] [Abstract][Full Text] [Related]
10. AQW051, a novel and selective nicotinic acetylcholine receptor α7 partial agonist, reduces l-Dopa-induced dyskinesias and extends the duration of l-Dopa effects in parkinsonian monkeys.
Di Paolo T; Grégoire L; Feuerbach D; Elbast W; Weiss M; Gomez-Mancilla B
Parkinsonism Relat Disord; 2014 Nov; 20(11):1119-23. PubMed ID: 25172125
[TBL] [Abstract][Full Text] [Related]
11. Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
Johnston TH; Fox SH; McIldowie MJ; Piggott MJ; Brotchie JM
J Pharmacol Exp Ther; 2010 Jun; 333(3):865-73. PubMed ID: 20231306
[TBL] [Abstract][Full Text] [Related]
12. The selective mu-opioid receptor antagonist ADL5510 reduces levodopa-induced dyskinesia without affecting antiparkinsonian action in MPTP-lesioned macaque model of Parkinson's disease.
Koprich JB; Fox SH; Johnston TH; Goodman A; Le Bourdonnec B; Dolle RE; DeHaven RN; DeHaven-Hudkins DL; Little PJ; Brotchie JM
Mov Disord; 2011 Jun; 26(7):1225-33. PubMed ID: 21465551
[TBL] [Abstract][Full Text] [Related]
13. MPEP, an mGlu5 receptor antagonist, reduces the development of L-DOPA-induced motor complications in de novo parkinsonian monkeys: biochemical correlates.
Morin N; Grégoire L; Morissette M; Desrayaud S; Gomez-Mancilla B; Gasparini F; Di Paolo T
Neuropharmacology; 2013 Mar; 66():355-64. PubMed ID: 22884464
[TBL] [Abstract][Full Text] [Related]
14. Effects of L-tryptophan on L-DOPA-induced dyskinesia in the L-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque model of Parkinson's disease.
Ko WK; Li Q; Bezard E
Neurosci Lett; 2014 Apr; 566():72-6. PubMed ID: 24572591
[TBL] [Abstract][Full Text] [Related]
15. Effect of memantine on L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease.
Tronci E; Fidalgo C; Zianni E; Collu M; Stancampiano R; Morelli M; Gardoni F; Carta M
Neuroscience; 2014 Apr; 265():245-52. PubMed ID: 24486947
[TBL] [Abstract][Full Text] [Related]
16. Safinamide reduces dyskinesias and prolongs L-DOPA antiparkinsonian effect in parkinsonian monkeys.
Grégoire L; Jourdain VA; Townsend M; Roach A; Di Paolo T
Parkinsonism Relat Disord; 2013 May; 19(5):508-14. PubMed ID: 23402994
[TBL] [Abstract][Full Text] [Related]
17. Pridopidine, a clinic-ready compound, reduces 3,4-dihydroxyphenylalanine-induced dyskinesia in Parkinsonian macaques.
Johnston TH; Geva M; Steiner L; Orbach A; Papapetropoulos S; Savola JM; Reynolds IJ; Ravenscroft P; Hill M; Fox SH; Brotchie JM; Laufer R; Hayden MR
Mov Disord; 2019 May; 34(5):708-716. PubMed ID: 30575996
[TBL] [Abstract][Full Text] [Related]
18. Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys.
Grégoire L; Samadi P; Graham J; Bédard PJ; Bartoszyk GD; Di Paolo T
Parkinsonism Relat Disord; 2009 Jul; 15(6):445-52. PubMed ID: 19196540
[TBL] [Abstract][Full Text] [Related]
19. Changes of AMPA receptors in MPTP monkeys with levodopa-induced dyskinesias.
Ouattara B; Hoyer D; Grégoire L; Morissette M; Gasparini F; Gomez-Mancilla B; Di Paolo T
Neuroscience; 2010 Jun; 167(4):1160-7. PubMed ID: 20303391
[TBL] [Abstract][Full Text] [Related]
20. Effect of histamine H2 receptor antagonism on levodopa-induced dyskinesia in the MPTP-macaque model of Parkinson's disease.
Johnston TH; van der Meij A; Brotchie JM; Fox SH
Mov Disord; 2010 Jul; 25(10):1379-90. PubMed ID: 20310030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
